Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-hepatitis B ribozyme - Ribozyme Pharmaceuticals

Drug Profile

Anti-hepatitis B ribozyme - Ribozyme Pharmaceuticals

Alternative Names: HepBzyme

Latest Information Update: 08 Jan 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sirna Therapeutics
  • Class
  • Mechanism of Action RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 13 Nov 2002 Suspended - Phase-I for Hepatitis B in USA (SC)
  • 21 Nov 2001 Preclinical data have been added to the Viral Infections antimicrobial activity section
  • 09 Mar 2001 Phase-I clinical trials for Hepatitis B in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top